Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + finotonlimab with induction chemotherapy for locally advanced hypopharyngeal cancer
ChiCTR2600132900Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, finotonlimab, docetaxel and carboplatin in squamous cell carcinoma of the hypopharynx, sponsored by Fujian Medical University Union Hospital. Primary endpoint: Objective Response Rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
anlotinibfinotonlimabdocetaxelcarboplatin
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2600132900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132900.